Psychedelic Medicine: 67% PTSD Remission vs 32% Placebo
FDA granted Breakthrough Therapy Designation to psilocybin (2018, 2019) and MDMA (2017). Phase 3 trials show results that would be front-page news if any other drug achieved them.
67%PTSD remission rate — MDMA-assisted therapy
32%Remission rate — therapy + placebo (control)
3FDA Breakthrough Therapy Designations granted
54%Depression remission — psilocybin vs 11% antidepressant
Choose your depth. The data doesn't change — just the explanation.
Some medicines that used to be illegal — like the chemical in magic mushrooms (psilocybin) and MDMA (ecstasy) — are now being studied to help people who are really suffering from trauma and depression. In proper clinical trials with therapists guiding the session, they work way better than anything we currently have. The FDA is taking it seriously.
MDMA-assisted therapy for PTSD showed 67% remission in MAPS Phase 3 trials (MAPP1 and MAPP2), compared to 32% in the therapy + placebo arm. Psilocybin for depression showed 54% remission vs 11% for escitalopram in a Nature Medicine RCT (Carhart-Harris et al., 2021). The FDA granted Breakthrough Therapy Designation — a fast-track pathway — to MDMA for PTSD (2017) and psilocybin for depression (2018, 2019). Both remain Schedule I controlled substances federally.
MAPS MAPP1 (Mitchell et al., 2021, Nature Medicine): n=90, CAPS-5 primary endpoint, MDMA arm 67% no longer meeting PTSD diagnostic criteria. MAPP2 (Mitchell et al., 2023): n=104, CAPS-5 mean change -23.7 MDMA vs -14.8 placebo. FDA rejected MDMA approval in Aug 2024, citing missing data and requesting new trial. Psilocybin: Carhart-Harris 2021 (Nature Medicine) n=59, BDI endpoint. COMP360 Phase 2 (COMPASS Pathways): -8.1 QIDS-SR vs -3.6 placebo. Safety concern: psilocybin SSRI interaction attenuates effect size. Political economy: Schedule I status creates massive regulatory overhead; Phase 3 costs 3-5× analogous drug trials due to set-and-setting requirements.
MAPS clinical trial registry: ClinicalTrials.gov NCT03537014 (MAPP1), NCT04077437 (MAPP2). COMPASS Pathways Phase 2b: NCT03775200. Imperial College psilocybin vs escitalopram: NCT03429075 (Nature Medicine DOI: 10.1038/s41591-021-01164-z). FDA BTD database: fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy. MAPS Phase 3 data: maps.org/research/mdma/ptsd.
Clinical Trial Results Comparison
Head-to-head data from Phase 2 and Phase 3 randomized controlled trials — the same standard of evidence used to approve any other medication.
MDMA-Assisted Therapy for PTSD
% no longer meeting PTSD diagnostic criteria at 18-week follow-up (MAPS Phase 3)
Psilocybin vs. Leading Antidepressant
Depression remission rates — Imperial College RCT (Nature Medicine 2021)
FDA Approval Pipeline — Psychedelic Therapeutics
Current trial phase by compound and indication
🔬 The Treatment Gap This Would Fill
8.7 million Americans have PTSD. Only 53% respond to current first-line treatments (SSRIs + CBT). That leaves ~4 million people treatment-resistant — many of them veterans. MDMA-assisted therapy showed particular efficacy in this population. Psilocybin is targeting major depressive disorder (280 million patients globally), treatment-resistant depression (~30% of MDD patients), and end-of-life anxiety. The market opportunity exceeds $100 billion, but the Schedule I status means clinical-grade manufacturing, therapist training overhead, and legal complexity are currently massive barriers.